

**BIOGRAPHICAL SKETCH**

Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.  
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME <b>Vivien Chen, PhD</b>		POSITION TITLE Professor of Epidemiology	
eRA COMMONS USER NAME (credential, e.g., agency login) VIVIENCHEN		Deputy Director for Science, Louisiana Tumor Registry	
EDUCATION/TRAINING ( <i>Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.</i> )			
INSTITUTION AND LOCATION	DEGREE (if applicable)	YEAR(s)	FIELD OF STUDY
Hong Kong Baptist College, Hong Kong	BSc	1969	Biology
University of Oklahoma, College of Health	MPH	1973	Community Health
University of Oklahoma, School of Public Health	PhD	1978	Epidemiology

**A. PERSONAL STATEMENT**

I have been the Director of Louisiana Tumor Registry for 20+ years and the PI of both the NCI SEER contract and the CDC-NPCR grant. I have extensive experience in cancer surveillance and in directing scientific, technical and fiscal aspects of many registry-related funded projects. I have held numerous leadership positions nationally and internationally, including President and Board of Directors of North American Association of Central Cancer Registries, Executive Committee of WHO/IARC's International Association of Cancer Registries, IOM's National Cancer Policy Board and its ad hoc committee on *Assessing Improvement in Cancer Care in Georgia*, National Quality Forum's Steering Committee on Quality of Care Measures, CDC's End of Life Work Group, Advisory Board of Intercultural Cancer Council. As the current Deputy Director of Science, I ensure registry data are being used extensively and appropriately for clinical care and delivery research. As the PI of the federally-funded project of "Enhancing Cancer Registry Data System for Comparative Effectiveness Research", I have enhanced Louisiana registry data by linkages with secondary datasets, including Medicaid and collecting additional tumor biomarkers that are both prognostic and predictive of treatment response. I am actively involved in research on cancer disparities, quality of cancer care and barriers to compliance of guideline treatments. Given the disparities observed in LA and MS, I will continue to conduct and support cancer care delivery research in the socioeconomically disadvantaged and medically underserved populations.

**B. POSITIONS AND HONORS****Positions and Employment**

1969-1972 Instructor (Biology), Hong Kong Christian College  
 1978-1979 Adjunct Assistant Professor, Dept. of Biostatistics & Epidemiology, Univ of Oklahoma HSC  
 1980-1982 Assistant Professor, Tulane School of Public Health and Tropical Medicine  
 1982-1989 Assistant Professor, Dept. of Pathology, Louisiana State University Medical Center  
 1989-1996 Associate Professor, Dept. of Pathology, Louisiana State University Medical Center  
 1991-2012 Director, Louisiana Tumor Registry  
 1996-2004 Professor and Chief, Epidemiology Section, Department of Public Health and Preventive Medicine, School of Medicine, LSUHSC  
 2004-2010 Professor and Program Director of Epidemiology, School of Public Health, LSUHSC  
 2010-present Professor School of Public Health  
 2012-present Deputy Director for Science

**Honors and Awards**

1978 Dean's Prize Award, University of Oklahoma HSC for Excellence in Research  
 1978 National Merit Award, Delta Omega Society, Outstanding Achievement in Public Health  
 1998 Distinguished Service Award, North American Association of Central Cancer Registries  
 1998 Pfizer Award for Excellence in Research, Education and Patient Care, LSUHSC  
 1999 Champion in Public Health, Tulane University School of Public Health & Tropical Medicine  
 2001 Pfizer/Giorgianni Professorship of Public Health, LSUHSC  
 2005 Calum S. Muir Memorial Award, North American Association of Central Cancer Registries

2008 Spirit Award, American Cancer Society  
 2009 Special Award for Long-term Dedication, Louisiana Cancer Registrars Association  
 2011 2011 Women of the Year Honoree, New Orleans City Business

### Selected Appointments

1992-1998 Member of Executive Committee and Representative of North America, International Association of Cancer Registries (IACR), WHO  
 1993-1996 Member, NCI Biometry and Epidemiology Contract Review Committee  
 1994-1998 Board of Directors, North American Association of Central Cancer Registries (NAACCR)  
 1996-1997 Ad hoc Advisory Board, NCI Breast Cancer Specimen and Data Information System  
 1997, 2001 External Review and Program Planning Committee, CDC Cancer Conference  
 1997-1998 Member, NCI Cancer Surveillance Implementation Group  
 1998 California Cancer Research Grant Review Committee  
 1998; 2002 Advisory and Program Planning Committee, CDC National Program of Cancer Registries  
 1998-2000 Board of Directors, American College of Epidemiology  
 1999-2002 National Cancer Policy Board, Institute of Medicine (IOM), National Academy of Sciences (NAS)  
 2000-2004 President-Elect, President, Past President, N. American Association Central Cancer Registries  
 2002-2004 Member, CDC End of Life Work Group  
 2002-2004 Member, CDC/NCI/NAACCR United States Cancer Statistics Work Group  
 2003 Member, Site Visit Team to 10 cancer registries in China, IACR, WHO  
 2003-2004 Advisory Board Member, Intercultural Cancer Council  
 2003-2005 Ad hoc Committee on *Assessing Improvements in Cancer Care in Georgia*, National Cancer Policy Board, Institute of Medicine, NAS  
 2004-present Steering Committee, Quality of Cancer Care Measures, National Quality Forum  
 2007-2008 Committee on "Gulf War and Health: Updated Literature Review of Depleted Uranium", Institute of Medicine, NAS  
 2010-2011 Strategic Plan Oversight Committee, North American Association of Central Cancer Registries (NAACCR)  
 2010-2011 Chair of Nominating Committee, NAACCR  
 2011-2012 Member, Nominating Committee, IACR, WHO

### Professional Organizations

Fellow: American College of Epidemiology

Member: Society for Epidemiologic Research, American Association for Cancer Research, American Society of Preventive Oncology, American Public Health Association, the Society of Sigma Xi, Delta Omega Society

### C. PUBLICATIONS (Total over 100, selected from 2009 and those relevant)

1. Eley JW, Hill HA, **Chen VW**, Austin DF, Welsey MN, Greenberg RS, Coates RJ, Herman AA, Muss HB, Redmond CK, Edward BK, Kurman R. Racial differences in survival from breast cancer : Results of the National Cancer Institute Black/White Cancer Survival study. *JAMA* 1994;272:947-954.
2. **Chen VW**, Fenoglio-Preiser CM, Wu XC, et al. Aggressiveness of colon carcinoma in blacks and whites *Cancer Epidemiology, Biomarkers & Prevention* 6: 1087-1083, 1997.
3. Wu XC, **Chen VW**, Andrews PA, Hsieh MC. Treatment patterns for Stage III colon cancer and factors related to receipt of postoperative chemotherapy in Louisiana. *J La Med Soc* 2004;156:35-39.
4. Wu XC, **Chen VW**, Chen LC, Hsieh MC, et al. Initial treatment patterns for clinically localized prostate cancer and factors associated with the therapy in Louisiana. *J La Med Soc* 2005; 157:188-194.
5. Wu XC, Cokkinides V, **Chen VW**, Nadel M, Ren Y, Martin J, Ellison GL. Association of subsite-specific colorectal cancer incidence rates and stage at diagnosis with county-level poverty, by race and sex, 1998 2001. *Cancer* 107 (5 Suppl): 1121-7, September 2006
6. Wu XC, Richardson LC, Kahn AR, Fulton JP, Cress RD, Shen TF, Wolf HJ, Bolick-Aldrich S, **Chen VW**. Survival Difference between Non-Hispanic Black and Non-Hispanic White Women with Localized Breast Cancer: The Impact of Guideline-Concordant Therapy. *J Natl Med Assoc*, May 2008; 100(5): 490-498.

7. Byers TE, Wolf HJ, Bauer KR, Bolick-Aldrich S, **Chen VW**, Finch JL, Fulton JP, Schymura MJ, Shen T, Van Heest S, Yin X for the Patterns of Care Study Group. The Impact of Socioeconomic Status on Survival after Cancer in the United States: Findings from the National Program of Cancer Registries' Patterns of Care Study. *Cancer*, August 2008; 113(3):582-591.
8. Clegg LX, Reichman ME, Miller BA, Hankey BF, Singh GK, Lin YD, Goodman MT, Lynch CF, Schwartz SM, **Chen VW**, Bernstein L, Gomez SL, Graff JJ, Lin CC, Johnson NJ, Edwards BK. Impact of socioeconomic status on cancer incidence and stage at diagnosis: selected findings from the SEER: National Longitudinal Mortality Study. *Cancer Causes and Control*, Vol. 20 (4): 417-435, May 2009. PMC2711979
9. Wu, XC, Andrews P, **Chen VW**, Groves FD. Incidence of extranodal non-Hodgkin lymphomas among whites, blacks, and Asians/Pacific Islanders in the United States: Anatomic site and histology differences. *Cancer Epidemiol* 2009;33:337-346. Nov, 2009.
10. Watson M, Johnson CJ, **Chen VW**, Thomas CC, Weir HK, Sherman R, Cockburn M, Jackson-Thompson J, Saraiya M. Melanoma surveillance in the United States: overview of methods. *J Am Acad Derm*. 2011 Nov;65 (5 Suppl 1):S6-16. PMID: 22018069
11. Hsieh MC, Pareti LA, **Chen VW**. Using NAPIIA to Improve the Accuracy of Asian Race Codes in Registry Data. *Journal of Registry Management*, 2011;38(4): 190-195
12. Hsieh MC, Velasco C, Wu XC, Pareti LA, Andrews PA, **Chen VW**. Influence of socioeconomic status and Hospital type on disparities of lymph node evaluation in colon cancer patients. *Cancer*. 2012. Mar 15; 118(6): 1675-1683. PMC3767484.
13. Wu XC, Lund MJ, Kimmick GG, Richardson LC, Sabatino SA, **Chen VW**, Fleming ST, Morris CR, Huang B, Trentham-Dietz A, Lipscomb J. Influence of Race, Socioeconomic Status, Insurance, and Hospital Type on Receipt of Guideline-Concordant Adjuvant Systemic Therapy for Locoregional Breast Cancers. *J Clin Oncology*. 2012 Jan;30(2):121-4.
14. Smith AW, Bellizzi KM, Keegan THM, Zebrack B, **Chen VW**, Neale AV, Hamilton A, Shnorhavorian M, Lynch F, and the AYA HOPE Study Collaborative Group. Health-related Quality of Life of Adolescent and Young Adult Cancer Patients in the United States: the AYA HOPE Study. *J Clin Oncol*. 2013 Jun 10;31(17):2136-45. PMCID: PMC3731979.
15. Hsieh MC, Wu XC, Andrews PA, **Chen VW**. Racial and Ethnic Disparities in Incidence and Trend of Soft Tissue Sarcoma among Adolescents and Young Adults: United States, 1995-2008. *J Adolesc Young Adult Oncol*. 2013 Jul; 2(3):89-94. PMC3778995.

#### **D. RESEARCH SUPPORT: Ongoing Research Support**

##### **Patient Center Outcome Research (PCOR)**

HHS/CDC/IFC-Macro

01/01/2014 – 02/28/2015

The objective of this study is to follow a cohort of breast and colorectal cancer patients diagnosed in 2011 for recurrence and progression of cancer and to compare the effectiveness of different treatments

Role: PI

##### **Surveillance, Epidemiology, and End Results (SEER) Program: Louisiana**

HHSN261201000030C (N01-PC-2010-00030C)

08/01/2010 – 07/31/2017

The main goal of this program is to operate an efficient statewide cancer surveillance program, to provide cancer incidence and survival estimates, and to participate in collaborative cancer research.

Role: Principal Investigator (2010-12); Co-PI (2012- present)

##### **National Cancer Prevention and Control Program/National Program of Cancer Registries**

CDC: U58-DP000769

06/30/2012 – 06/29/2017

Cooperative Agreement: Centers for Disease Control and Prevention (CDC)

The major goals of this program are to enhance the Registry to maintain the standards of completeness, timeliness and data quality; to provide early detection of breast and cervical cancers for under- and uninsured women in Louisiana; and to develop and implement a comprehensive statewide Cancer Control Plan.

Role: Principal Investigator

**Enhancing Cancer Registries for Early Case Capture (ECC) of Pediatric and Young Adult Cancers**

CDC: 1U58DP003805-01

9/30/2011-9/29/2014

Cooperative Agreement: Centers for Disease Control and Prevention (CDC)

The objectives of this ECC project are to enhance registry operations and build sustainable infrastructure for timely pediatric cancer database for the surveillance, clinical, and research communities.

Role: Principal Investigator

**Generating Critical Patient-Centered Information for Decision Making in Localized Prostate Cancer**

PCORI: CE-12-11-4667 (Subcontract: VUMC 41761)

8/1/2013-7/31/2015

Role: Co-investigator of LSU Team (PI-Wu)

The main goal of this study is to generate patient-centered information for decision making in localized prostate cancer.

**Comparative Effectiveness of Modern Therapies for Localized Prostate Cancer**

AHRQ: 1R01HS022640-01

12/1/2015-11/30/2016

Role: Co-Investigator of Louisiana (PI-Wu)

The main goal of this study is to compare the effectiveness and outcomes of different treatment options for localized prostate cancer

**Validation of PROMIS in Diverse Patient Populations**

NIH: U01AR057971-01

09/30/2009 – 09/29/2014

The objective of this multicenter study is to evaluate the measurement properties of Patient-Reported Outcomes Measurement Information System (PROMIS) item banks and use the banks to assess differences in population-based patient outcomes including health-related quality of life in diverse cancer population.

Role: Co-Investigator of Louisiana (PI-Wu)

**Selected Completed Research Support****Enhancing Cancer Registry Data System for Comparative Effectiveness Research**

CDC/IFC-Macro: Sub. #: 635-243-10S1566

12/01/2010 – 09/31/2013

The main goal is to develop sustainable methods to enhance registry for supporting Comparative Effectiveness Research and collect detailed information on treatment, stage, biomarkers and comorbidities for assessing quality of cancer for colorectal and female breast cancers as well as chronic myeloid leukemia.

Role: Principal Investigator

**Comparative Effectiveness of Treatment for Localized Prostate Cancer**

AHRQ: R01-HS019356

09/01/2010 – 08/31/2013

Role: Co-Investigator of Louisiana (PI-Wu)

**Adolescent and Young Adult Health Outcome Patient Experience and Follow-Up**

HHSN261200544002C-Supplement (N01-PC-54402)

09/01/2007 – 07/31/2010

The objective of this study is to assess the feasibility of an expanded pattern of care study among 15-39 years old cancer patients who were diagnosed with non-Hodgkins lymphoma, ALL, sarcoma and germ cell tumors.

Role: Co-Investigator (PI-Wu)

**Breast and Prostate Cancer Data Quality and Patterns of Care Study**

UOI-DP000253-02

09/01/2005 – 09/29/2010

Research Project Cooperative Agreement, CDC

The purpose of this study are: (i) to examine the patterns of treatment for breast and prostate cancers; (ii) to determine the proportion of breast cancer patients receiving standard care and factors associated with the receipt; and (iii) to evaluate data quality of these cancers in registry database.

Role: Co-Investigator (PI-Wu)

**Surveillance for Precancerous Cervical Lesions among Cancer Registries to monitor the Impact of Human Papillomavirus Vaccine in the United States**

35127-8S-1119

10/01/2009 – 03/31/2011

The major goal of this project is to estimate the prevalence of CIN3 lesions through a state central cancer registry to estimate the population prevalence.

Role: Co Investigator (PI-Peters)